Literature DB >> 1376041

Lymphokine production by B cells from normal and HIV-infected individuals.

J H Kehrl1, P Rieckmann, E Kozlow, A S Fauci.   

Abstract

Interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) are both secreted by in vivo-activated normal B cells and by in vivo-activated B cells from patients with polyclonal B-cell activation, including individuals infected with the human immunodeficiency virus (HIV). Furthermore, IL-6 and TNF-alpha are involved in autocrine and paracrine regulation of human B-cell differentiation. Following in vitro stimulation of normal B cells with Staphylococcus aureus Cowan strain I and IL-2, there is a rapid but brief increase in supernatant levels of TNF-alpha. There is also an initial increase followed by a subsequent and more sustained increase in IL-6 production. The secondary rise in IL-6 production is dependent upon the prior production of TNF-alpha. There is no significant difference in IL-6 and TNF-alpha secretion by CD5 positive versus CD5 negative tonsillar B cells. Ig production by normal in vitro-activated B cells and freshly isolated B cells from patients with hypergammaglobulinemia is largely dependent upon TNF-alpha and IL-6 production. As another measure of B-cell TNF-alpha and IL-6 production, freshly isolated B cells from HIV-infected individuals induce virus production by chronically HIV-infected cells in which HIV production is known to be triggered by a variety of cytokines. By contrast, freshly isolated B cells from normal controls fail to increase HIV production unless they are stimulated in vitro. Thus, the spontaneous production of IL-6 and TNF-alpha by B cells from individuals infected with HIV may contribute to viral expression as well as to the hypergammaglobulinemia often associated with HIV infection.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1376041     DOI: 10.1111/j.1749-6632.1992.tb24617.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  7 in total

1.  Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease.

Authors:  Thomas S Uldrick; Mark N Polizzotto; Karen Aleman; Kathleen M Wyvill; Vickie Marshall; Denise Whitby; Victoria Wang; Stefania Pittaluga; Deirdre O'Mahony; Seth M Steinberg; Richard F Little; Robert Yarchoan
Journal:  Blood       Date:  2014-10-20       Impact factor: 22.113

2.  Regulation of Epstein-Barr virus promoters in oral epithelial cells and lymphocytes.

Authors:  L A Lagenaur; J M Palefsky
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

3.  A splenic marginal zone-like peripheral blood CD27+B220- B cell population is preferentially depleted in HIV type 1-infected individuals.

Authors:  Matthew Morrow; Antonio Valentin; Richard Little; Robert Yarchoan; George N Pavlakis
Journal:  AIDS Res Hum Retroviruses       Date:  2008-04       Impact factor: 2.205

4.  Human immunodeficiency virus type 1-associated CD40 ligand transactivates B lymphocytes and promotes infection of CD4+ T cells.

Authors:  Geneviève Martin; Jocelyn Roy; Corinne Barat; Michel Ouellet; Caroline Gilbert; Michel J Tremblay
Journal:  J Virol       Date:  2007-03-28       Impact factor: 5.103

5.  A role for TLR signaling during B cell activation in antiretroviral-treated HIV individuals.

Authors:  Basile Siewe; Ali Keshavarzian; Audrey French; Patricia Demarais; Alan Landay
Journal:  AIDS Res Hum Retroviruses       Date:  2013-08-16       Impact factor: 2.205

6.  Exploring the biological function of immune cell-related genes in human immunodeficiency virus (HIV)-1 infection based on weighted gene co-expression network analysis (WGCNA).

Authors:  Ruojing Bai; Zhen Li; Shiyun Lv; Wei Hua; Lili Dai; Hao Wu
Journal:  BMC Med Genomics       Date:  2022-09-19       Impact factor: 3.622

7.  FcRL4 Expression Identifies a Pro-inflammatory B Cell Subset in Viremic HIV-Infected Subjects.

Authors:  Basile Siewe; Allison J Nipper; Haewon Sohn; Jack T Stapleton; Alan Landay
Journal:  Front Immunol       Date:  2017-10-20       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.